Supratherapeutic Tacrolimus Concentrations With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients Requiring Hospitalization: A Case Series Using Rifampin for Reversal-Reference-Cited by-同舟云学术

Supratherapeutic Tacrolimus Concentrations With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients Requiring Hospitalization: A Case Series Using Rifampin for Reversal

Published:2022-05-13 Issue:7 Volume:9 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Rose Dusten T¹²^ORCID,Gandhi Saurin M³,Bedard Rachael A¹⁴,Mondy Kristin E⁵,Chu Alexander L⁶,Gamble Kelly C¹,Gee Amanda T¹,Kundra Monica A³,Williams Amber L¹,Lee Brian K⁴⁷

Affiliation:

1. Department of Pharmacy, Ascension Seton, Dell Seton Medical at The University of Texas , Austin, Texas , USA

2. College of Pharmacy, University of Texas at Austin , Austin, Texas , USA

3. Department of Internal Medicine, Dell Medical School, University of Texas at Austin , Austin, Texas , USA

4. Kidney and Pancreas Transplant Program, Dell Seton Medical Center, University of Texas at Austin , Austin, Texas , USA

5. Division of Infectious Diseases, Department of Internal Medicine, Dell Medical School, University of Texas at Austin , Austin, Texas , USA

6. Department of Medical Education, Dell Medical School, University of Texas at Austin , Austin, Texas , USA

7. Division of Nephrology, Department of Internal Medicine, Dell Seton Medical Center, University of Texas at Austin , Austin, Texas , USA

Abstract

Abstract Nirmatrelvir/ritonavir was recently granted emergency use authorization for mild to moderate coronavirus disease 2019. Drug–drug interactions between ritonavir and tacrolimus are underappreciated by nontransplant providers. We describe 2 solid organ transplant recipients prescribed nirmatrelvir/ritonavir for outpatient use who developed tacrolimus toxicity requiring hospitalization and were managed with rifampin for toxicity reversal.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

https://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofac238/43698839/ofac238.pdf

Reference19 articles.

1. COVID data tracker;Centers for Disease Control and Prevention,2022

2. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir;Badri;Am J Transplant,2015

3. Drug-drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: a review;van Maarseveen;AIDS Patient Care STDS,2012

4. Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy;Katzenmaier;Clin Pharmacol Ther,2011

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the drug-drug interactions management system for appropriate use of nirmatrelvir/ritonavir: a retrospective observational study;Journal of Pharmaceutical Health Care and Sciences;2024-09-03

2. Effect of rifampicin administration on CYP induction in a dermatomyositis patient with vasospastic angina attributable to nilmatrelvir/ritonavir-induced blood tacrolimus elevation: A case report;Journal of Infection and Chemotherapy;2024-09

3. COVID-19 in the immunocompromised host;COVID-19: An Update;2024-09-01

4. Influence of ensitrelvir or nirmatrelvir/ritonavir on tacrolimus clearance in kidney transplant recipients: a single-center case series;Journal of Pharmaceutical Health Care and Sciences;2024-07-10

5. Case report and literature review: management of Paxlovid (nirmatrelvir/ritonavir)-induced acute tacrolimus toxicity in a patient with systemic lupus erythematosus;Frontiers in Pharmacology;2024-06-19